These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1518439)

  • 1. Proceedings of the discussion, "Tolerability and safety of Sandostatin".
    Wass JA; Popovic V; Chayvialle JA
    Metabolism; 1992 Sep; 41(9 Suppl 2):80-2. PubMed ID: 1518439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proceedings of the discussion: 'Tolerability and safety of Sandostatin'.
    Popovic V; Chayvialle JA; Wass JA
    Digestion; 1993; 54 Suppl 1():104-6. PubMed ID: 8359564
    [No Abstract]   [Full Text] [Related]  

  • 3. Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.
    Shi YF; Zhu XF; Harris AG; Zhang JX; Dai Q
    J Clin Endocrinol Metab; 1993 Jan; 76(1):32-7. PubMed ID: 8421099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A risk-benefit assessment of octreotide in the treatment of acromegaly.
    van der Lely AJ; de Herder WW; Lamberts SW
    Drug Saf; 1997 Nov; 17(5):317-24. PubMed ID: 9391775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies.
    Pivonello R; Muscogiuri G; Holder G; Paul M; Sarp S; Lesogor A; Jordaan P; Eisinger J; Colao A
    Endocrine; 2018 Apr; 60(1):65-72. PubMed ID: 29116540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.
    Newman CB; Melmed S; Snyder PJ; Young WF; Boyajy LD; Levy R; Stewart WN; Klibanski A; Molitch ME; Gagel RF
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2768-75. PubMed ID: 7673422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sonography of gallbladder abnormalities in acromegaly patients following octreotide and ursodiol therapy: incidence and time course.
    Avila NA; Shawker TH; Roach P; Bradford MH; Skarulis MC; Eastman R
    J Clin Ultrasound; 1998; 26(6):289-94. PubMed ID: 9641388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly.
    Plöckinger U; Dienemann D; Quabbe HJ
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1658-62. PubMed ID: 2229321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
    Ho KY; Weissberger AJ; Marbach P; Lazarus L
    Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatolithiasis (intrahepatic stone) during octreotide therapy for acromegaly: a case report.
    Sheehan MT; Nippoldt TB
    Pituitary; 2000 Dec; 3(4):227-30. PubMed ID: 11788010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and tolerability of octreotide treatment in acromegaly.
    Christensen SE; Weeke J; Orskov H; Kaal A; Lund E; Jørgensen J; Harris AG
    Metabolism; 1992 Sep; 41(9 Suppl 2):44-50. PubMed ID: 1518433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment of acromegaly with a long-acting analogue of somatostatin, octreotide.
    Page MD; Millward ME; Taylor A; Preece M; Hourihan M; Hall R; Scanlon MF
    Q J Med; 1990 Feb; 74(274):189-201. PubMed ID: 2111918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proceedings of the workshop, "Practical approaches to the diagnosis and treatment of acromegaly".
    Liuzzi A; Sobrinho LG; Besser GM
    Metabolism; 1992 Sep; 41(9 Suppl 2):87-90. PubMed ID: 1518440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly.
    Stewart PM; Kane KF; Stewart SE; Lancranjan I; Sheppard MC
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3267-72. PubMed ID: 7593436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoration of gallbladder contractility after withdrawal of long-term octreotide therapy in acromegalic patients.
    Shi YF; Zhu XF; Harris AG; Zhang JX; Deng JY
    Acta Endocrinol (Copenh); 1993 Sep; 129(3):207-12. PubMed ID: 8212985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment of acromegaly with octreotide (Sandostatin).
    Page MD; Millward ME; Hourihan M; Hall R; Scanlon NF
    Horm Res; 1990; 33 Suppl 1():20-30; discussion 30-1. PubMed ID: 2192978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management.
    Redfern JS; Fortuner WJ
    Am J Gastroenterol; 1995 Jul; 90(7):1042-52. PubMed ID: 7611194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of continuous subcutaneous infusion of octreotide on gallstone formation in acromegalic patients.
    Tauber JP; Poncet MF; Harris AG; Barthel HR; Simonetta-Chateauneuf C; Buscail L; Bayard F
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3262-6. PubMed ID: 7593435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sandostatin LAR in acromegalic patients: a dose-range study.
    Fløgstad AK; Halse J; Haldorsen T; Lancranjan I; Marbach P; Bruns C; Jervell J
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3601-7. PubMed ID: 8530606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.